Koji Sasaki
Researcher Next ID · RN-035950
Researcher · Medicine
The University of Texas MD Anderson Cancer Center
Houston, Japan
- Works count
- 1,132
- Citation count
- 15,829
- H-index
- 63
- i10-index
- 277
Research interests
Publications
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02103-8
Management of chronic myeloid leukemia in 2023 – common ground and common sense
Blood Cancer Journal · 2023 · https://doi.org/10.1038/s41408-023-00823-9
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Cancer · 2021 · 10.1002/cncr.33458
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03736
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Blood · 2021 · https://doi.org/10.1182/blood.2020009984
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30210-6
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Haematologica · 2020 · https://doi.org/10.3324/haematol.2020.252569
Ibrutinib and Venetoclax for First-Line Treatment of CLL
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1900574
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
The Lancet Haematology · 2018 · 10.1016/s2352-3026(18)30176-5
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30011-1
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.77.6757
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
Blood · 2017 · https://doi.org/10.1182/blood-2017-06-788497
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis
Cancer · 2016 · https://doi.org/10.1002/cncr.30231
Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
Blood · 2016 · 10.1182/blood-2016-03-707562
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
The Lancet Haematology · 2015 · 10.1016/s2352-3026(15)00048-4
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00207-7
Current projects
No projects listed.